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ABSTRACT
Introduction: There is an unmet need for well-
tolerated antiepileptic drugs (AEDs) that effec-
tively control focal onset seizures. This study
aimed to evaluate the economic value of new
AEDs in the treatment of focal onset seizure,
with or without secondary generalization, in
Finnish adults and adolescents with epilepsy,
comparing brivaracetam with perampanel as
adjunctive AEDs.
Methods: Economic value was assessed using
cost-utility analysis. Periods of AED initiation,
titration, response assessment (seizure free-
dom, C 50% reduction, no response), switching
in no response or treatment-emergent adverse
events (TEAEs), and death were simulated using
a discrete-event simulation model. Responses
and switching were simulated based on a com-
prehensive Bayesian network meta-analysis.
The primary modeled outcome was the 3%/year
discounted incremental cost-effectiveness ratio
(ICER). Discounted quality-adjusted life-years
(QALYs), payer costs (year 2017 Euro) per
patient, and net monetary benefit (NMB) were
secondary outcomes. Probabilistic and compre-
hensive deterministic sensitivity analyses were
conducted.
Results: Brivaracetam was more efficacious and
had fewer TEAEs than perampanel and other
AEDs. Modeled average 5-year QALYs and costs
were 3.671 and €28,297 for brivaracetam and
3.611 and €27,979 for perampanel, respectively.
The resulting ICER for brivaracetam versus
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perampanel was only €5345/QALY gained in a
deterministic base case scenario. Brivaracetam
had a positive NMB and high probability of
cost-effectiveness of €1190 and 71% or €1944
and 80% with the assumed willingness to pay of
€25,358 or €38,036/QALY gained, respectively.
The primary result was robust, with a positive
NMB persistent in all sensitivity analysis sce-
narios. When switching from brivaracetam to
perampanel was excluded from the modeling or
switching from perampanel to brivaracetam was
included, brivaracetam was cost-saving and
more effective than perampanel (dominant).
Conclusion: These simulated comparisons
demonstrated that brivaracetam was more
effective and potentially also more affordable
than perampanel. Thus, brivaracetam is likely a
cost-effective and net beneficial alternative to
perampanel for treatment of focal onset
seizures.
Plain Language Summary: Plain language
summary available for this article.
Keywords: Brivaracetam; Economic evaluation;
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Key Summary Points
Why carry out this study?
While published evidence on benefits and
costs of different treatment strategies is
lacking, there is a significant unmet need
for well-tolerated, effective, and affordable
antiepileptic drugs for focal seizure
epilepsy
Authors examined whether adjunctive
treatment brivaracetam would provide
acceptable additional effectiveness for
potential additional costs compared with
treatment with adjunctive perampanel
What was learned from the study?
Brivaracetam had a high probability of
being cost-effective and providing
acceptable additional benefit for
additional costs compared with
perampanel
With earlier brivaracetam initiation
resulting in more health benefits at lower
costs than achieved with later
brivaracetam initiation, treatment with
brivaracetam also has potential to be more
affordable than treatment with
perampanel
Indirect costs, such as work absenteeism
and early retirement, associated with
poorly managed epilepsy have an
enormous burden for epilepsy patients
and society alike and should be examined
and addressed in future studies
PLAIN LANGUAGE SUMMARY
Published evidence on benefits and costs of
different treatment strategies for focal seizure
epilepsy in Finland is lacking. We examined
whether using brivaracetam as an add-on
antiepileptic drug (AED) would provide accept-
able additional health benefits for accept-
able additional costs versus treatment with
perampanel, i.e., if brivaracetam was cost-ef-
fective compared with perampanel.
We simulated the progression of epilepsy
over a 5-year period, including treatment path-
ways, subsequent treatments, and other health
care utilization. In the base case analysis, we
assumed that brivaracetam or perampanel was
added to treatment of two AEDs at the begin-
ning of the simulation. We conducted extensive
deterministic (based on mean values) and
probabilistic (based on specified distributions)
sensitivity analyses to evaluate the impact of
different model inputs and treatment patterns.
This included adding brivaracetam or peram-
panel to one AED. The treatment effects were
estimated as quality-adjusted life-years, denot-
ing survival multiplied by the expected quality
of life.
Our simulations indicated that brivaracetam
has a high probability of being cost-effective
and likely provides sufficient additional benefit
for additional costs compared with perampanel.
Results also indicated that brivaracetam is likely
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to be cheaper and more effective than peram-
panel if: (1) brivaracetam is used in addition to
only one AED, (2) perampanel is not used after
brivaracetam, or (3) brivaracetam is also used
after perampanel treatment.
INTRODUCTION
Epilepsy is a symptomatic brain disorder char-
acterized by epileptic seizures and neurobio-
logic, cognitive, psychologic, and social
consequences [1]. The seizures are caused by
abnormal excessive or synchronous neuronal
activity in the brain and are classified as gener-
alized or focal onset seizures. Focal onset sei-
zures were previously also known as partial-
onset seizures [2, 3]. In a generalized seizure,
neuronal activity begins in both hemispheres,
in contrast to a focal onset seizure, which orig-
inates within specific neuronal networks within
one cerebral hemisphere. Secondary general-
ization, or focal to bilateral tonic-clonic seizure,
is initially localized to one area of the brain but
then disseminates to both hemispheres [4].
Prevalence of epilepsy was estimated to be
approximately 5.3–6.3 cases per 1000 individu-
als in Europe [5] and 6.3 per 1000 individuals
for active epilepsy (one or more seizures during
the previous 5 years) in Finland [6]. In Finland,
the incidence of treated epilepsy was estimated
in 2002 to be 0.444 per 1000 males and 0.406
per 1000 females in the 16–64 year age range
[7]. The incidence of epilepsy increases with age
[5, 7], and epilepsy with focal onset seizures is
the most prevalent form among adults [5]. In
2017, a total of 59,972 patients in Finland who
had relevant reimbursement number codes
received a special reimbursement for their
antiepileptic drugs (AEDs) [8], resulting in an
approximate prevalence of 10.9 pharmaceuti-
cally treated epilepsy patients per 1000
individuals.
Epilepsy reduces health-related quality of life
(HRQoL) [9] and increases mortality [9–11],
psychiatric comorbidity [12, 13], and economic
burden [14–16]. The primary aim of epilepsy
treatment is to minimize the number of seizures
experienced by patients and to ensure that there
are as few treatment-emergent adverse events
(TEAEs) as possible. Sillanpa¨a¨ et al. [15] esti-
mated that epilepsy costs (in Euros) were €176
million in Finland in 2004, 54.5% of which
included costs from registries that were indirect
costs resulting from sick leave, early retirement,
and premature deaths. In Sweden, indirect costs
declined between 2005 and 2011 on increasing
the use of AEDs [16].
At the same time, a higher proportion (30%)
of patients with polytherapy achieved seizure
freedom in 2014 than in 2004 (22%), indicating
that some patients with focal onset seizures
benefited from newer AEDs as an adjunctive
therapy in real life [17]. Lower seizure frequency
is, in turn, associated with a higher HRQoL
[18–20] and a decreased incidence of accidents
[9, 21].
Whereas use of older AEDs (e.g., carba-
mazepine, phenobarbital, phenytoin, sodium
valproate) is associated with poorer tolerability
and leads to more drug-drug interactions with
other AEDs, use of newer AEDs (e.g., brivarac-
etam, perampanel) can result in improved tol-
erability with fewer drug-drug interactions.
Brivaracetam is a well-tolerated [22–28] and
efficacious [25–29] ‘‘next-generation racetam’’
that requires no uptitration to achieve the
therapeutic dose range. Furthermore, previous
treatment failures with other AEDs or racetams
(e.g., levetiracetam) do not preclude the use of
brivaracetam [30].
The cost-effectiveness and budget impact of,
for example, lacosamide in the treatment of
epilepsy patients with focal onset seizures have
been previously assessed in Finland [31]. How-
ever, based on a literature search of the PubMed
database, no assessments have been published
on the cost-effectiveness of the most recent
AEDs (brivaracetam and perampanel) in Fin-
land. Therefore, an analysis was needed to assess
the economic value (i.e., modeled cost, effec-
tiveness, and cost-effectiveness) of brivaracetam
and perampanel in the treatment of patients
with focal onset seizures.
METHODS
The economic value of brivaracetam was asses-
sed with cost-utility analysis using a discrete
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event simulation model (DESM) developed for
this purpose (see Charokopou et al. [32] and
Va¨a¨ta¨inen et al. [33]). The present analysis is
based on the health economic analysis submit-
ted as part of an application of the reasonable
wholesale price and reimbursement for bri-
varacetam in Finland (previously reported as
poster presentation; Va¨a¨ta¨inen et al. [33]). Thus,
it is in line with the official cost-effectiveness
analysis guideline by the Finnish Pharmaceuti-
cals Pricing Board [34], a health technology
assessment guideline by the Finnish Medicines
Agency [35], recent work by the national Cur-
rent Care treatment guideline working group
[36], and evidence-based medicine. The present
analysis applies the Patients-Intervention-
Comparator-Outcome-Setting-Time-Effects-Per-
spective-Sensitivity analysis (PICOSTEPS
[37, 38]) principle, which describes the essential
components of health economic evaluation in
order of importance and has been successfully
applied in multiple health economic evaluation
tasks [36–41].
Patients
The relevant modeled patient cohort included
adult and adolescent (C 16 years of age)
patients with epilepsy with focal onset seizures,
with or without secondary generalization (focal
to bilateral tonic–clonic seizures). Based on
clinical practice, the modeled patients had
typically used several AEDs before inclusion and
used two concurrent AEDs at the model begin-
ning; brivaracetam or perampanel was used as
the third concurrent AED. Generally, the bri-
varacetam and perampanel target population is
drug-resistant and difficult to treat.
At model baseline, patients were on average
38.5 [standard deviation (SD) 13.0] years of age,
based on the average age in placebo-controlled
brivaracetam trials [42], with a potential age
range of 16–99 years. Patients were modeled to
have on average 10.0 seizures per month based
on brivaracetam trials [42] (median 9.175 sei-
zures/28 days, i.e., 9.175/28 9 365.25/12 sei-
zures per month). Because of lack of data,
modeled SD was set to 2.0 seizures per month,
based on a 20% assumption, and the minimum
rate was set to 0.08 seizures per month, based
on the rationale that patients had at least one
seizure per year. By sex, 49.4% of the patients
were male [42], and approximately 0.2% were of
Han Chinese ethnicity [43]. The effects of dif-
ferent baseline-relevant patient characteristics
were explored in the sensitivity analyses.
Regarding compliance with ethics guideli-
nes, this article is based on previously con-
ducted studies and does not contain any studies
with human participants or animals performed
by any of the authors. In addition, because this
article reports the results of a simulated cost
utility analysis and not a randomized controlled
or other trial directly involving human subjects,
this study is not registered with any clinical trial
database.
Intervention and Comparator
Although the pharmaceutical treatment of epi-
lepsy is always individualized, preferences for
the first choice AEDs generally follow the
national recommendation in Finland [44]. The
modeled cost-effectiveness of brivaracetam was
compared with the most relevant, recent, and
similarly positioned adjunctive AED that had
correspondent patient population expectations
and adjunctive position in care criteria in the
treatment of focal onset seizures in adult
patients as a third concurrent AED. This AED
was perampanel, which was considered the
most relevant comparator for brivaracetam
because it was used in the same patient sub-
group and treatment line. In addition, peram-
panel was the most recently reimbursed AED
before brivaracetam and was accepted as a
comparator to brivaracetam for the Finnish
reimbursement application.
In the modeled base case comparison,
patients had either brivaracetam or perampanel
added as a third concomitant AED to their
existing treatment of two concurrent AEDs
(‘‘base AEDs’’). This was founded on observed
and expected real-world use in Finnish clinical
practice. Base AEDs remained identical in both
comparison arms, but they could affect the use
of subsequent AED alternatives. The base AED
combinations by proportions were: 79%
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oxcarbazepine plus lacosamide, pregabalin, or
zonisamide; 7% eslicarbazepine plus lacosa-
mide, pregabalin, or zonisamide; 7% lacosamide
plus pregabalin, zonisamide, or eslicarbazepine;
or 7% lamotrigine plus lacosamide, pregabalin,
zonisamide, or eslicarbazepine.
Brivaracetam or perampanel was added to
one of these combinations. If subsequent treat-
ment was required after failing on brivaracetam
then treatment alternatives could include zon-
isamide, pregabalin, lamotrigine, or peram-
panel, depending on which AEDs were used
previously. In the perampanel arm of the
model, the alternatives for subsequent treat-
ments, after failing on perampanel, included
zonisamide, pregabalin, or lamotrigine.
In the base case scenario, the subsequent
AEDs after failing on brivaracetam were
assumed to include perampanel as a subsequent
treatment alternative. This was a conservative
assumption (i.e., not favoring brivaracetam),
because it assumed that brivaracetam did not
replace perampanel but rather delayed its use.
The costs of perampanel thus influenced both
intervention and comparator. The effects of
different treatment sequencing (e.g., excluding
perampanel use after brivaracetam, including
brivaracetam after perampanel, adding bri-
varacetam or perampanel only in addition to
one base AED, as well as different combinations
of base AEDs and subsequent AEDs) were
examined in the sensitivity analyses.
In the base case analyses, both brivaracetam
and perampanel doses were based on average
doses examined in their respective clinical tri-
als. These corresponded closely to brivaracetam
50 mg twice daily, which was the most common
brivaracetam dose used in Finnish practice, and
a perampanel dose of 8 mg once daily. Bri-
varacetam response is dose-independent and,
moreover, in Finland has the same price for all
therapeutic dose formulations. In contrast,
perampanel has effects that are dose-dependent
and pricing that varies according to tablet
strength. Thus, different perampanel doses
together with different concomitant and sub-
sequent AEDs were explored in the sensitivity
analyses. Sensitivity analyses also included a
scenario in which brivaracetam was compared
with placebo.
Outcomes
The primary outcome of this economic evalua-
tion was the incremental cost-effectiveness ratio
(ICER), measured as the difference (D) in simu-
lated costs (in Euro) divided by the difference in
simulated effectiveness [measured as quality-
adjusted life-years (QALYs)]. Costs were esti-
mated based on resources used and their
respective unit costs. QALY is integral and is
denoted as modeled survival multiplied by
expected modeled average HRQoL.
Secondary outcomes included mean total
costs, mean total QALYs gained, and net mon-
etary benefit (NMB). Because the main aim of
antiepileptic treatment is to improve the
HRQoL of patients [44], use of QALYs is the
most appropriate measure of effectiveness.
Setting
Individual patient-based DESM with Microsoft
Excel user interface and R (v. 3.2.1) statistical
software engine was used to simulate the com-
parison and to capture all relevant data and
clinically meaningful events based on clinical
consultation with neurologists specializing in
epilepsy (Fig. 1; see also Charokopou et al. [32],
Va¨a¨ta¨inen et al. [33]). The DESM generated a
virtual cohort of 20,000 epilepsy patients with
focal onset seizures, each of whom followed an
individualized clinical pathway according to
their time-dependent characteristics, response
to each treatment (treatment history), and risk
of other events.
The DESM included three defined lines of
monotherapy and a maximum of five defined
lines of adjunctive therapy and was in line with
Finnish care guidelines [44]. Modeled events
included AED initiations, titration period (i.e.,
the AED dose was gradually increased until the
patient showed optimal response), response
assessment period, AED switching when there
was no response, early and late TEAEs, time on
AED, epilepsy surgery (only included in a sen-
sitivity analysis scenario), and death.
In the DESM, patient’s seizure frequency
influenced their monitoring, period of response
assessment, and response to therapy. Ineffective
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treatments were not repeated in the pathway,
and inappropriate/contraindicated treatment
sequences and/or combinations were not used.
Reasons for avoiding some combinations
included contraindications (e.g., topiramate
and zonisamide), no additional benefit from the
combination (e.g., carbamazepine and eslicar-
bazepine or oxcarbazepine and eslicarbazepine
and oxcarbazepine or gabapentin and prega-
balin), and risk of psychologic TEAEs (e.g.,
levetiracetam and topiramate).
In the case of TEAEs or no acceptable re-
sponse (seizure freedom or C 50% reduction in
seizure frequency) in the DESM, the most
recently added AED was swapped for a newly
selected drug from AEDs available in the next
treatment line. An AED could be added when
the patient had no acceptable response and had
fewer than three concurrent AEDs. Discontinu-
ation of long-term treatment because of late
breakthrough seizures or loss of response was
also considered. Tapering down or stopping
AED treatment completely was not modeled
because of rarity in this patient group and dis-
ease severity in Finland.
In the DESM, different AEDs were associated
with varied titration and drug acquisition costs,
which were cumulated based on modeled times
on-titration and on-treatment. Monitoring
costs were differentiated between time with and
Fig. 1 Simpliﬁed description of the discrete-event simula-
tion model (DESM). AED antiepileptic drug, TEAE early
or late onset treatment-emergent adverse event. Dashed
lines denote the decisions and states excluded from the
base case analysis. 1. Patient characteristics included, e.g.,
age, sex, seizure frequency, and ethnicity. 2. Included only
in a sensitivity analysis scenario; in the base case modeling
patients were assumed to have been assessed for surgery
earlier based on the Finnish practice. Patients will only be
assessed for the surgery once. 3. The base case modeling
was initiated here, when brivaracetam or perampanel was
added as a third AED on top of two base AEDs. 4.
Acceptable response was seizure free or having at least a
50% reduction in seizure frequency. 5. Only relevant for a
sensitivity analysis scenario. In the base case scenario,
patients always had at least three concomitant AEDs. 6.
Transition to death could happen at any time (absorbing,
i.e., patients exit the model)
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without seizures. Separate HRQoL was assigned
depending on the patients’ treatment response
and survival. Cumulative QALYs were estimated
based on time spent on each of these responses
and were stopped at death or at the end of the
modeled time horizon. Both costs and QALYs
were aggregated at the end of the modeled time
horizon.
Time
A 5-year time horizon was considered sufficient
to capture the relevant clinical pathway. In
addition, knowledge of long-term events,
effects, and discontinuations beyond 5 years is
limited and more uncertain. A discount rate of
3% per year was used because the time horizon
exceeded 1 year [34, 35]. The effects of time
horizons and discount rates on the results were
examined in the sensitivity analyses.
Effects
Although the ultimate goal of epilepsy treat-
ment is seizure freedom [44], only 30% and 20%
of all Finnish epilepsy patients with focal onset
seizures and users of three concurrent AEDs
achieve seizure freedom, respectively [17]. Thus,
aiming for a 50% reduction in seizure frequency
is clinically relevant in the patient population
considered in the present analyses.
To inform the DESM, a systematic literature
review (SLR) and comprehensive Bayesian net-
work meta-analysis (BNMA) were conducted
(see Borghs et al. [45], Charokopou et al. [46]) to
parameterize probabilities of seizure free-
dom, C 50% reduction in seizure frequency,
and discontinuations resulting from TEAEs. The
present analyses utilized a version of the BNMA
used in price and reimbursed applications for
Finland and the UK (Charokopou et al. [32],
Va¨a¨ta¨inen et al. [33]). Compared with the pub-
lished BNMA (Borghs et al. [45], Charokopou
et al. [46]), the version utilized here includes
one lacosamide and one levetiracetam study
less, comprising in total 63 studies instead of 65
studies in the published BNMA (see Electronic
Appendix 1 for further details).
The median and mean values with corre-
sponding 2.5–97.5 posterior distribution per-
centiles are reported in Table 1. The mean
values and distributions were applied in the
base case and in the probabilistic sensitivity
analysis (PSA). Median values were used in the
sensitivity analysis scenario. No interaction
effects between concomitant AEDs were inclu-
ded because of a lack of data.
To put the BNMA results into a practical
perspective, probabilities (and associated poste-
rior odds; see Soini et al. [47]) that brivaracetam
is better than perampanel were estimated,
reflecting the greater effectiveness of brivarac-
etam. The probabilities of brivaracetam treat-
ment being better and its posterior odds were
82% and 4.6, respectively, for the seizure free-
dom, 69% and 2.2 for the[ 50% reduction in
seizures, and 80% and 4.0 for no TEAE status.
In contrast to brivaracetam, perampanel had
different dosing schemes resulting in varying
costs and effects. Thus, the dosing scheme for
perampanel was varied and was tested based on
a separate fixed-effects meta-analysis (FEMA) of
five placebo-controlled brivaracetam and five
placebo-controlled perampanel trials identified
in the SLR for the comprehensive BNMA (see
Electronic Appendix 1). Table 1 also reports the
dose-dependent perampanel effects based on
the FEMA.
Late TEAEs were not included in the simu-
lation because of a lack of evidence, and early
TEAEs not resulting in treatment discontinua-
tion were assumed to be similar between AEDs.
The time on an AED was sampled for those
patients who achieved an acceptable response
to the AED and continued beyond the response
assessment period.
As a result of lack of drug-specific evidence,
treatment persistence after the initial response
evaluation was simulated using probabilities
from the National Institute for Health and Care
Excellence (NICE) reference case (see NICE
2011, table 8 [48]) from the UK. Consequently,
long-term discontinuation because of treatment
failure was modeled to decline progressively
over time, from an initial 12.6% (6-monthly
risk) during the 6–12-month period after treat-
ment initiation to 2.5% during the period 54–-
60 months after treatment initiation.
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Health-Related Quality of Life
HRQoL in the DESM was modeled to be
dependent upon the achieved level of treatment
response by each patient, which was based on
the significant difference in HRQoL depending
on treatment responses [19, 20]. HRQoL effects
Table 1 Efﬁcacy and safety probabilities of AEDs based on the comprehensive BNMA of 63 trials and the different dosing
schemes of perampanel based on the FEMA of ﬁve brivaracetam and ﬁve perampanel trials
BNMA
outcome
Seizure freedom (%) ‡ 50% seizure reduction (%) Discontinuation due to adverse
event (%)
AED Median Mean (2.5–97.5
percentile)a
Median Mean (2.5–97.5
percentile)a
Median Mean (2.5–97.5
percentile)a
Brivaracetam 9.38 12.55 (1.8–41.44) 32.18 32.99 (15.58–55.25) 7.92 8.59 (3.55–17.51)
Carbamazepine 6.08b 7.56 (1.4–22.05)b 35.03b 35.74 (17.78–57.59)b 17.10b 17.78 (8.57–30.73)b
Eslicarbazepine 3.71 4.88 (0.76–15.94) 33.14 33.92 (16.24–56.02) 12.55 13.31 (5.97–24.99)
Lacosamide 4.20 6.38 (0.74–24.37) 30.86 31.79 (14.36–54.65) 14.43 15.50 (6.59–30.38)
Lamotrigine 5.00 6.22 (1.23–18.51) 28.18 29.15 (12.68–51.11) 10.32 10.95 (4.90–20.75)
Levetiracetam 6.64 8.10 (1.65–22.99) 44.38 44.58 (24.11–66.56) 9.74 10.34 (4.67–19.56)
Oxcarbazepine 7.89 10.23 (1.59–32.11) 36.75 37.56 (17.54–61.53) 21.33 13.31 (5.97–24.99)
Perampanel 4.50 6.20 (0.85–21.93) 29.45 30.45 (13.93–52.19) 10.77 11.56 (4.71–23.08)
Pregabalin 3.50 4.39 (0.83–13.08) 40.96 41.35 (21.57–63.75) 12.97 13.68 (6.54–24.58)
Sodium
valproate
6.08b 7.56 (1.4–22.05)b 35.03b 35.74 (17.78–57.59)b 17.10b 17.78 (8.57–30.73)b
Topiramate 7.23 8.99 (1.61–27.09) 35.30 35.98 (16.74–59.06) 12.72 13.49 (5.72–26.18)
Zonisamide 1.90 2.56 (0.38–8.68) 33.73 34.39 (16.73–56.99) 11.61 12.38 (5.19–24.14)
FEMA outcomec Seizure freedom (%) > 50% seizure reduction (%) Discontinuation because
of adverse event (%)
AED Mean Mean Mean
Brivaracetam 10.66 33.36 8.31
Perampanel 4 mg 5.11 28.59 8.77
Perampanel 6 mgd 5.11d 31.13d 8.77d
Perampanel 8 mg 5.11 33.67 8.77
Perampanel 10 mgd 5.76d 33.67d 15.29d
Perampanel 12 mg 6.40 33.67 21.81
See Electronic Appendix 1 for more details regarding BNMA and FEMA
AED antiepileptic drug, BNMA Bayesian network meta-analysis, FEMA ﬁxed-effect meta-analysis
a Percentiles of posterior distribution produced by BNMA
b Assumed to be equal to the average of eslicarbazepine and oxcarbazepine (lack or limitations of evidence)
c Relative effects estimated from FEMA and anchored to BNMA mean placebo rates of 1.48%, 18.56%, and 5.33% for
seizure freedom, C 50% reduction in seizures and discontinuation due to adverse events, respectively
d Based on the linear interpolation of effects from the neighbor doses (no trial data available)
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associated with AEDs were assumed to take
place only after completion of the titration
period.
The HRQoL values used were 0.869 for sei-
zure freedom, 0.805 for C 50% and 0.623
for\ 50% reduction in seizures (unpublished
EQ-5D-3L data from SANAD study; see Mulhern
et al. [20]). Given the Finnish population-level
survey data [49], these utility values were rea-
sonable and potentially conservative: the aver-
age EQ-5D-3L scores were 0.911 and 0.868,
respectively, among the Finnish general popu-
lation who was 30–44 years of age and the
population with neurologic disorders who was
30–44 years of age irrespective of their diagno-
sis, health state, or treatment [49]. The effect of
using generic versus disease-specific HRQoL
values was explored in sensitivity analyses by
using NEWQOL-6D values (unpublished data
from SANAD study; see Mulhern et al. [20]).
Additionally, the effect of using an extremely
high HRQoL value based on Selai et al. [19],
who reported EQ-5D values higher than those
observed in the general Finnish population [49],
was also explored.
Mortality
Age- and disease-specific mortalities were
applied based on age-specific mortality risks of
the general population [50], and adjustment to
the relative all-cause mortality of patients
experiencing seizures was done with a stan-
dardized mortality ratio of 2.55 (95% confi-
dence interval 2.24, 2.91) [11]. Seizure-free
patients had increased mortality risk compared
with the general population [10], which was
implemented using an odds ratio of 1.399,
based on results from Fazel et al. [10]: (focal
epilepsy odds of 112/12,841)/(general popula-
tion odds of 4129/660,869). The effect of
assuming that there was no increased mortality
for seizure-free patients was examined in a
sensitivity analysis scenario.
Changes in patient’s response status or age
resulted in the re-estimation of mortality risk.
The risk of death at 100 years of age was fixed at
100%.
Perspective
Based on the Finnish health economic evalua-
tion guidelines [34, 35], only direct health care
costs and travel were included, and a third-party
payer perspective was applied. Thus, titration
and maintenance AEDs, TEAEs, treatment, visit,
hospitalization, and patient co-payment costs
were included. Indirect costs, such as sickness
allowances, pensions, absenteeism, presen-
teeism, education, unemployment, household
chores, taxes and other income transfers, and
time costs as a consequence of epilepsy, were
excluded in the base case analysis to ensure a
conservative perspective for brivaracetam.
The impact of the perspective was simulated
in the sensitivity analyses because of its signifi-
cance in epilepsy [15] and the significant dif-
ferences observed among indirect costs for
other long-term diseases in Finland [51, 52]. The
modeled sensitivity analysis scenarios ranged
from a narrow direct health care costs (exclud-
ing travel costs) perspective to a wide societal
perspective, where, for example, short-term
absenteeism, presenteeism, education, unem-
ployment, and household chores were included
[51, 52]. This was in addition to traditional
societal indirect costs of sick leave, early retire-
ment, and premature death (absenteeism; [15]).
Costs
Base case analysis considered costs related to
medication, treatment initiation, and switching
as well as monitoring. Drug use and costs, as
well as health care resource use and associated
costs, are summarized in Table 2.
Epilepsy treatments were excluded from
generics substitution in Finland. That is,
patients were not offered cheaper alternatives to
the prescribed epilepsy medication brand and
formulation in the pharmacy, and the full
reimbursement was paid for the prescribed
medication, even if cheaper alternatives were
available. However, a conservative approach
was assumed in the simulation, and the January
2019 cost [53] of the most affordable retail drugs
(excluding value-added tax) and package sizes
formulated as capsules or tablets were used.
Titration periods of perampanel and the
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Table 2 Resource use and costs
Phase Titration perioda Maintenanceb
AED Duration, scheme, and dosing Drug
costc
Daily dosage Daily
drug
costc
Drug use patterns and associated costs
Brivaracetam No titration required; titration not modeled N/A 2 9 50 mg €5.53
Carbamazepined Only as base-AED in the model; titration not modeled N/A 2 9 400 mg €0.39
Eslicarbazepinee Total 30 days: 2 9 200 mg 15 days ? 1 9 800 mg 15 days €76.47 1000 mg €7.42
Lacosamidee Total 21 days: 2 9 50 mg 7 days ? 2 9 100 mg
14 days ? 2 9 150 mg 7 days
€78.04 2 9 200 mg €6.40
Lamotrigine Total 70 days: 25 mg 14 days ? 2 9 25 mg
14 days ? 2 9 50 mg 14 days ? 100 ? 50 mg
14 days ? 2 9 100 mg 7 days ? 100 ? 150 mg 7 days
€48.04 200 ? 100 mg €1.32
Levetiracetamd,e Total 28 days: 2 9 500 mg 28 days €37.53 2 9 1000 mg €2.52
Oxcarbazepine Only as base-AED in the model; titration not modeled N/A 2 9 600 mg €1.09
Perampanel Total 28 days: 2 mg 7 days ? 4 mg 7 days ? 2 ? 4 mg
7 days ? 2 9 4 mg 7 days
€222.74 8 mg €5.61
Pregabalin Total 14 days: 2 9 75 mg 7 days ? 2 9 150 mg 7 days €14.22 2 9 225 mg €1.06
Sodium
valproated,e
Total 28 days: 2 9 300 mg for 14 days ? increased by 300 mg
every 7 days up to 5 9 300 mg
€17.43 3 9 500 mg €0.75
Topiramated,e Total 56 days: 25 mg 7 days ? 50 mg 7 days ? 75 mg
7 days ? 100 mg 7 days ? 150 mg 7 days ? 200 mg
7 days ? 250 mg 7 days ? 300 mg 7 days
€61.34 200 ? 150 mg €2.62
Zonisamide Total 28 days: 2 9 25 mg 7 days ? 2 9 50 mg
7 days ? 2 9 100 mg 7 days ? 2 9 125 mg 7 days
€101.74 200 ? 150 mg €4.52
Resource (special care) Annual use,
seizure free
Annual use,
not seizure free
Unit cost Daily cost,
seizure free
Daily cost, not
seizure free
Resources and costs associated with routine monitoring by seizure freedom status (free vs. not free)f
Inpatient 0.01 0.16 €3132 €0.09 €1.37
A&E visit 0.02 0.27 €471 €0.03 €0.35
Outpatient visit 0.50 3.00 €351 €0.48 €2.88
Nurse visit 0.50 2.00 €153 €0.21 €0.84
Nurse call 0.00 4.00 €38 €0.00 €0.42
Traveling 1.03 2.00 €37 €0.11 €0.56
Total €0.91 €6.41
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subsequent AEDs (rounded to the closest full
pack) used after brivaracetam or perampanel
were modeled based on the summaries of pro-
duct characteristics (SPC) and a study by Fish-
man et al. [54]. AED dosing at the maintenance
phase was based on Finnish data published by
Ma¨kinen et al. [17]. Defined daily doses (DDDs)
and recommended doses as described in the SPC
were used to supplement the maintenance
dosing inputs, where needed.
The health care section of latest official full
year Finnish Communal Expenses Index [55]
was used to inflate the national Finnish health
care unit costs [56] to 2017 values, which were
applied to other health care costs, excluding
drug costs. The transportation section of the
Finnish Consumer Price Index [57] was applied
to inflate the travel costs [58] to 2017 values.
Resource use for monitoring and TEAE man-
agement was based on published results and
Finnish practice. Because of lack of data, all AED
initiations and switches that were modeled
incur identical resource utilization. The effects
of lower and higher cost inputs were examined
in the sensitivity analyses.
In Finnish practice and from a proposal
achieved by international consensus [59],
patients were typically assessed for eligibility for
epilepsy surgery after two AEDs had been tried.
Thus, epileptic surgery was modeled only in a
sensitivity analysis scenario. When costs [60]
were inflated to the 2017 level [55], the cost for
surgery assessment was €2111 and that for
actual surgery was €18,204. It was estimated
that approximately 10% of Finnish patients
were assessed for surgery annually, with
approximately 13% of those assessed found to
be eligible and approximately 50% of the oper-
ated patients seizure free until death (cured,
without AED, no drug costs assumed).
Willingness to Pay
The interpretation of primary outcome was
complicated by the lack of official willingness-
to-pay thresholds [61, 62], which could be used
as the limits for additional cost to an additional
QALY gained in Finland.
In Finland, the UK thresholds (converted to
Euros) have previously been successfully applied
in a cost-effectiveness analysis [38]. This
Table 2 continued
Resource (special care) Use Unit cost Total cost
Resources and cost associated with start or switch of an AEDf
Outpatient 1.00 €471 €471
Nurse visit 1.00 €153 €153
Doctor phone call 0.83 €83 €69
Nurse phone call 1.67 €38 €64
Traveling 2.00 €37 €75
Total €832.23
A&E Accident and Emergency, AED antiepileptic drug, d days, DDD deﬁned daily dose, GP general practitioner (primary
care), SPC summary of product characteristics, ? followed by
a Titration adapted based on SPC and Fishman et al. [54]
b Maintenance dosing based on published Finnish data by Ma¨kinen et al. [17] as well as SPC and DDD where feasible and
needed
c Calculated using cheapest doses and pack sizes. For titration, wastage was avoided by using full packages. Drug costs
represent those valid as of January 2019
d AED is only included in sensitivity analysis
e AED titration is only included in the sensitivity analysis, otherwise a base AED
f All costs other than drug purchase prices represented at 2017 level [55]
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approach was extended by adjusting the UK
thresholds [63] for 2017 purchase power parity
[64]. The most plausible willingness-to-pay
threshold in non–end-of-life situations in the
UK is £20,000 (€25,358 in 2017 purchasing
power adjusted value), which may be plausible
in some cases up to £30,000 (€38,036) per QALY
gained. These thresholds could be potentially
valid for focal onset seizures in Finland and
were applied in this modeling study.
To transform the primary outcome to NMB,
these two different willingness-to-pay thresh-
olds (€25,358 and €38,036/QALY) were applied
to:
NMB ¼ DQALY due to the intervention
willingness to pay=
QALYD cost due to the intervention,
where D denotes the difference between bri-
varacetam and perampanel. The NMB can be
interpreted as cost savings that also cover health
benefits with the given willingness-to-pay
thresholds and enable straightforward cost-
benefit analysis-type interpretation of the cost-
effectiveness results (i.e., a positive result indi-
cates cost savings).
Sensitivity Analyses
Robustness of the modeled primary outcome
was evaluated using multiple simulated one-
and multi-way sensitivity analysis scenarios as
well as PSA. The sensitivity analysis scenarios
varied model inputs regarding patient, inter-
vention, comparator, time, effects, and per-
spective components using either (1) specific
inputs based on alternative sources or (2)
extreme changes assumed at ± 20% of the
inputs used in the base case scenario.
PSA was implemented based on known or
assumed (20% SD) distributions. Because of
complex DESM computation, PSA was not
conducted conventionally by iterating the
DESM for thousands of times with a stable co-
hort size. Instead, PSA results were generated
using the Sheffield Accelerated Value of Infor-
mation (SAVI) tool [65], which assessed param-
eter uncertainty in individual patient models.
SAVI used the output from smaller sampled
cohorts by applying nonparametric regression
to separate the variation attributed to parameter
values from individual patient variation [66].
The cost-effectiveness plane depicted the
joint distributions of modeled costs and QALYs.
Acceptability frontier [67] described the PSA-
based probability of cost-effectiveness for the
optimal strategy as the function of willingness
to pay [38].
RESULTS
During the modeled 5-year time horizon,
treatment with brivaracetam resulted in an
average additional QALY gain of 0.059 (? 1.6%)
compared with perampanel, with an average
additional cost of €318 (total ? 1.1%, on aver-
age €64 per year) per patient (Table 3). Conse-
quently, the resulting ICER, or the average cost
of one additional QALY gained with brivarac-
etam in comparison with perampanel, was only
€5345 per QALY gained in the base case
simulation.
NMB estimates for brivaracetam versus per-
ampanel were €1190 and €1944 per patient with
the assumed willingness to pay of €25,358 and
€38,036 per QALY gained, respectively. These
NMBs translate to 4.3% and 6.9% savings versus
the total direct costs of perampanel. Conse-
quently, from the perspective of NMB, each
25th or 16th relevant patient with focal onset
seizures could be treated cost-free with bri-
varacetam versus perampanel.
The biggest differences in effectiveness were
acquired during the first modeled AED. Drug
costs accounted for approximately 60.6% and
57.7% of total modeled costs in the brivarac-
etam and perampanel arms, respectively
(Table 3). Whereas the brivaracetam treatment
pathway was associated with total higher aver-
age AED costs (mainly because of assumed
potential subsequent perampanel treatment),
the monitoring and travel costs were lower on
average. In addition, the cumulative QALYs
with brivaracetam alone were substantially
higher (1.619) than with perampanel alone
(1.283), but the differences were leveled because
of modeled subsequent AEDs.
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Deterministic Sensitivity Analyses
In the extensive sensitivity analyses the results
were most sensitive to changes in the setting,
modeled time horizon, and large-scale changes
in HRQoL values (Table 4). However, brivarac-
etam remained the cost-effective option, and
base case simulation results were found to be
conservative (i.e., did not benefit brivaracetam).
The modeled sensitivity analyses also demon-
strated that brivaracetam should be used early
rather than late.
The modeled primary results were not sen-
sitive to changes in baseline patient character-
istics. In terms of comparator, brivaracetam was
more cost-effective versus the higher peram-
panel dosages than versus the lower perampanel
dosages. Compared with BNMA pooled average
placebo, brivaracetam was more effective and
less expensive (i.e., dominant).
When the setting was changed, brivaracetam
was dominant if: (1) perampanel was not mod-
eled to be used as a subsequent AED in the
patients receiving brivaracetam, (2) brivarac-
etam was added as a subsequent AED in the
patients receiving perampanel, or (3) the two
were assumed to be added to one base AED and
both were assumed to be used for the full
duration of the DESM. While changes in other
subsequent AED alternatives had only minor
effects on the results, the results were generally
more favorable for brivaracetam than the base
case.
Brivaracetam demonstrated better cost-ef-
fectiveness with shorter simulation time hori-
zons and worse cost-effectiveness with longer
time horizons. This can result from the constant
drug survival rates used for all AEDs, and from
the subsequent treatments used after peram-
panel, which are significantly more affordable
than perampanel itself. Based on the evidence
and development of the AED market, the 3- and
5-year scenarios were most relevant. In addi-
tion, changing discounting rates affected the
results meaningfully.
Although alternative modeled effects with
epilepsy-specific NEWQOL-6D HRQoL values
heavily favored the less effective perampanel,
the resulting ICER was only modestly higher
than in the base case. In addition, applying the
utility effects from the AED initiation had only
minimal effect on the base case result. However,
when the unrealistic (higher than average Fin-
nish general population [49]) HRQoL values
reported by Selai et al. [19] were used in an
extreme sensitivity analysis, the ICER increased.
Table 3 Base case results (5-year time horizon, 3% discount per year) per patient
Treatment Brivaracetam pathway Perampanel pathway Increment in
Investment Average costs (€) Average costs (€) Costs (€)
AEDs €17,148 €16,151 €997
Monitoring, seizures €10,166 €10,788 – €622
Traveling €983 €1041 – €58
Sum €28,297 €27,979 €318
Outcome QALYs QALYs QALYs
Brivaracetam/perampanel 1.619 1.283 0.336
First subsequent AED 0.748 0.876 – 0.128
Reserve AED 1.304 1.452 – 0.148
Sum 3.671 3.611 0.059
Outcome ICER: brivaracetam vs. perampanel, €/QALY gained €5345
AED antiepileptic drug, QALY quality-adjusted life-year, ICER incremental cost-effectiveness ratio
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Table 4 One- and multi-way sensitivity analysis results
Scenario Cost (€) QALYs ICER (€ per
QALY)
NMB
(€)BRV PER D BRV PER D
Base case €28,297 €27,979 €318 3.671 3.611 0.059 €5345 €1190
Patient
Mean age 20% lower: 30.8 years €27,850 €27,526 €324 3.614 3.549 0.066 €4947 €1339
Mean age 20% higher: 46.2 years €28,387 €27,981 €406 3.684 3.615 0.069 €5850 €1353
Male proportion 20% lower:
39.5%
€28,298 €27,955 €343 3.670 3.611 0.059 €5848 €1145
Male proportion 20% higher:
59.3%
€28,297 €27,976 €321 3.670 3.611 0.060 €5373 €1193
Seizure frequency 20% lower:
8.0/month
€28,297 €27,979 €318 3.671 3.611 0.059 €5347 €1189
Seizure frequency 20% higher:
12.0/month
€28,523 €28,201 €322 3.702 3.643 0.059 €5486 €1167
Comparatora
Speciﬁc perampanel dose: 4 mg
daily
€28,530 €28,027 €504 3.668 3.621 0.047 €10,632 €697
Speciﬁc perampanel dose: 6 mg
daily
€28,525 €28,110 €415 3.668 3.618 0.050 €8266 €858
Speciﬁc perampanel dose: 8 mg
daily
€28,520 €28,117 €404 3.660 3.609 0.051 €7930 €887
Speciﬁc perampanel dose: 10 mg
daily
€28,481 €28,023 €459 3.660 3.607 0.053 €8701 €878
Speciﬁc perampanel dose: 12 mg
daily
€28,455 €27,920 €535 3.661 3.597 0.064 €8344 €1091
Placebo comparison: no drug
costs; efﬁcacy and safety based
on BNMA placebo rates.
Means: SF: 1.48%, C 50%
reduction: 18.56%,
discontinuation due to adverse
events: 5.33%; no perampanel as
subsequent AED in the
brivaracetam arm
€27,550 €27,851 –€301 3.658 3.592 0.067 BRV dominant €1991
Setting
Perampanel omitted from the
brivaracetam arm
€27,550 €27,979 - €429 3.658 3.611 0.047 BRV dominant €1627
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Table 4 continued
Scenario Cost (€) QALYs ICER (€ per
QALY)
NMB
(€)BRV PER D BRV PER D
Brivaracetam added to
perampanel arm subsequent
treatment alternatives
€28,297 €28,599 - €302 3.671 3.650 0.020 BRV dominant €822
Brivaracetam and perampanel
added on top of only one base
AED, both are used for model
duration, with subsequent AEDs
added. Brivaracetam and
perampanel not used together
€25,157 €26,223 - €1067 3.686 3.640 0.046 BRV dominant €2230
Brivaracetam and perampanel
added on top of only one base
AED, both are used for model
duration, with subsequent AEDs
added. Brivaracetam and
perampanel may be used
together
€25,464 €26,448 - €984 3.687 3.656 0.031 BRV dominant €1764
Sodium valproate, topiramate,
lacosamide, and eslicarbazepine
included as additional reserve
AEDs to second (last)
subsequent treatment line
€28,319 €28,063 €256 3.683 3.634 0.049 €5223 €987
Sodium valproate, topiramate,
lacosamide, and eslicarbazepine
included as additional AEDs to
both subsequent treatment lines
€28,188 €28,110 €78 3.682 3.636 0.045 €1724 €1075
Base AEDs and subsequent
therapies based on wider variety
and including concomitant use
of brivaracetam with
levetiracetam
€25,420 €25,320 €99 3.691 3.645 0.047 €2130 €1082
Time
Discounting not applied €30,193 €29,838 €354 3.938 3.875 0.062 €5675 €1229
Discounting applied with higher
rate: 5% p.a.
€27,162 €26,866 €296 3.511 3.453 0.058 €5134 €1166
Time horizon shorter: 3 years €18,445 €18,307 €139 2.268 2.221 0.047 €2960 €1050
Time horizon longer: 10 years €50,677 €49,452 €1225 6.741 6.657 0.084 €14,616 €900
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Table 4 continued
Scenario Cost (€) QALYs ICER (€ per
QALY)
NMB
(€)BRV PER D BRV PER D
Effects
Epilepsy-speciﬁc NEWQOL-6D
scores: 0.849 for SF, 0.805
for C 50%, 0.692 for\ 50%
reduction
€28,297 €27,979 €318 3.679 3.642 0.037 €8584 €621
EQ-5D scores based on Selai
et al. [19]: 0.942 for SF, 0.900
for C 50%, 0.829 for\ 50%
reduction
€28,297 €27,979 €318 4.128 4.103 0.026 €12,317 €336
AEDs HRQoL effect starts at the
AED initiation
€28,297 €27,979 €318 3.683 3.631 0.052 €6092 €1005
Medians for the efﬁcacy and
safety parameters
€28,743 €28,205 €539 3.655 3.593 0.061 €8783 €1016
Epileptic surgery included in the
DESM
€28,730 €28,405 €325 3.682 3.620 0.062 €5260 €1242
Seizure free patient mortality
assumed to be same as in the
Finnish general population:
SMR = 1
€28,326 €27,963 €364 3.676 3.612 0.064 €5685 €1258
NSF monitoring costs 20%
lower: €5.13/day
€26,546 €26,103 €443 3.671 3.611 0.059 €7456 €1064
NSF monitoring costs 20%
higher: €7.70/day
€30,048 €29,856 €192 3.671 3.611 0.059 €3234 €1315
SF monitoring costs 20% lower:
€0.73/day
€28,241 €27,941 €300 3.671 3.611 0.059 €5050 €1207
SF monitoring costs 20% higher:
€1.09/day
€28,353 €28,018 €335 3.671 3.611 0.059 €5640 €1172
Treatment switching costs 20%
lower: €665.79
€27,874 €27,528 €346 3.671 3.611 0.059 €5814 €1162
Treatment switching costs 20%
higher: €998.68
€28,720 €28,431 €290 3.671 3.611 0.059 €4876 €1218
Perspective
Only direct medical: Travel
expenses excluded
€27,314 €26,939 €375 3.671 3.611 0.059 €6301 €1133
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Using medians instead of means for efficacy
parameters resulted in a slightly higher ICER.
Inclusion of surgery resulted in slightly higher
costs and health benefits but did not alter the
cost-effectiveness of brivaracetam. Overall, the
modeled results were not sensitive to even large
changes (± 20%) in monitoring and treatment-
switching costs.
Limiting the perspective of simulation by
excluding travel expenses resulted in a slightly
higher ICER and worse cost-effectiveness for
brivaracetam. On the other hand, inclusion of
expenses other than direct medical costs
improved the cost-effectiveness of brivarac-
etam. From traditional and wider societal per-
spectives, including indirect costs, brivaracetam
was dominant. Traditional and wider societal
perspectives also resulted in significantly higher
total costs for the comparators (2.5–2.6-fold and
8.2–8.8-fold compared with the base case,
respectively).
Probabilistic Sensitivity Analysis
The base case PSA simulation results were well
in line with the deterministic base case results
and the scenario sensitivity analyses. In PSA, the
brivaracetam and perampanel arms resulted in
mean outcomes of €28,088 and €27,353 and of
3.682 and 3.642 QALYs, respectively. Brivarac-
etam was associated with an average of 0.040
(95% credible interval - 0.015 to 0.100) addi-
tional QALYs at the average additional cost of
€555 (- 443 to 1470). The resulting average
ICER for brivaracetam versus perampanel was
€14,042/QALY gained.
Table 4 continued
Scenario Cost (€) QALYs ICER (€ per
QALY)
NMB
(€)BRV PER D BRV PER D
Direct non-medical costs
included based on Sillanpa¨a¨
et al. [15]: NSF and SF
monitoring costs excluding
traveling multiplied by 2.86b
€42,594 €42,511 €84 3.688 3.636 0.052 €1614 €1231
Traditional societal perspective:
Based on Sillanpa¨a¨ et al. [15]:
NSF and SF monitoring costs
excluding traveling multiplied by
6.29b
€71,059 €73,316 - €2257 3.671 3.611 0.059 BRV dominant €3764
Wider societal perspective:
Traditional societal cost NSF
and SF monitoring costs
multiplied by 4.13 [51]b
€233,258 €245,268 - €12,010 3.671 3.611 0.059 BRV dominant €13,517
AED antiepileptic drug, BNMA Bayesian network meta-analysis, BRV brivaracetam, Dominant more effective and also cost
saving, HRQoL health-related quality of life, ICER incremental cost-effectiveness ratio, D difference, NMB net monetary
beneﬁt with willingness to pay of €25,358 per QALY (purchasing parity adjusted 2017 value corresponding to £20,000 per
QALY), NSF non-seizure-free, p.a. per annum, PER perampanel, QALY quality-adjusted life-year, SF seizure free
a In comparator sensitivity analyses varying speciﬁc perampanel doses, both brivaracetam’s and perampanel’s relative efﬁcacy
and safety are based on ﬁxed-effect meta-analysis anchored to BNMA placebo rates
b Applied as relative difference, assuming the same ratio for NSF and SF monitoring costs. Ratios between total direct costs:
2.86 = 28 ? 52/€28 million annually in Finland, total costs 6.29 = 28 ? 52 ? 96/€28 million annually in Finland [15],
and between wider societal and traditional perspectives 4.13 = 1570/380 € per patient annually [51]
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Brivaracetam had 71% and 80% probability
of cost-effectiveness compared with perampanel
at the willingness to pay of €25,358 and €38,036
per QALY gained, respectively (Fig. 2). Bri-
varacetam was more effective and less costly
(i.e., dominant) in 12% of base case PSA
simulations.
In addition to the base case PSA, scenarios
with different relevant sequences were modeled
using the PSA. When the potential switch from
brivaracetam to perampanel was omitted, bri-
varacetam had a 65% probability of dominating
perampanel and 91% and 92% probability of
being cost-effective with the willingness-to-pay
thresholds of €25,358 and €38,046 per QALY,
respectively. Mean NMB with €25,358 per
QALY, cost savings, and QALYs gained were
€1964, €403, and 0.062 in the modeled 5-year
time horizon, respectively.
When the PSA was conducted in the setting
where brivaracetam and perampanel were
added on top of only one base AED, and both
were used for the model duration of 5 years,
brivaracetam had a 76% probability of domi-
nating perampanel and a 90% probability of
being cost-effective at both willingness-to-pay
thresholds. Mean NMB, cost savings, and
QALYs gained were €2192, €1114, and 0.043,
respectively.
DISCUSSION
This study simulated the cost-effectiveness of
using adjunctive brivaracetam compared with
perampanel in the treatment of focal onset sei-
zures in Finland. Recently, cost savings on use
of brivaracetam were demonstrated in Spain
[68], in contrast to the neutral budget impact
for the use of perampanel in the USA [69]; in
both instances brivaracetam was compared with
the current treatment practice. Here, we exten-
ded the setting to analysis of the economic
value, i.e., evaluation of the modeled costs,
effectiveness, and full cost-utility analysis also
including NMB—comparing these two recently
approved AEDs for treatment of focal onset
seizures and including quality-adjusted survival
measured as both QALYs and payers’ direct
costs.
The expected average ICER for adjunctive
brivaracetam versus adjunctive perampanel was
only €5345/QALY gained in our conservative
base case simulation. In the scenario analyses,
where switching from brivaracetam to peram-
panel was excluded, or switching from peram-
panel to brivaracetam was included,
brivaracetam demonstrated cost saving and was
more effective (dominant) compared with per-
ampanel. In a probabilistic base case scenario,
NMB per patient and probability of cost-effec-
tiveness for brivaracetam were high: €1190 and
71% or €1944 and 80% with the willingness to
pay of €25,358 or €38,036/QALY gained,
respectively. From the perspective of NMB, each
25th or 16th relevant epilepsy patient could be
Fig. 2 Results of the probabilistic sensitivity analysis.
a Cost-effectiveness plane (CEP) and b cost-effectiveness
acceptability curves (CEACs). Probabilistic sensitivity
analysis results were generated using 2000 DESM itera-
tions with cohorts of 500 patients. Marked point in CEP
denotes the average results, and the line denotes the
plausible willingness-to-pay threshold of €25,358 per
quality-adjusted life-years (QALYs) gained. Marked points
in CEAC denote the willingness to pay of €25,358 and
€38,036 per QALY gained
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treated without any loss (‘‘for free’’) with bri-
varacetam versus perampanel or 4.3% or 6.9%
of monetarized benefit (‘‘savings’’) could be
gained. Findings are in line with the previous
findings from the UK setting [32].
Based on the extensive sensitivity analyses,
brivaracetam was robustly cost-effective com-
pared with its most relevant single adjunctive
AED competitor, perampanel, in the Finnish
setting. When the potential switch from bri-
varacetam to perampanel was omitted, bri-
varacetam dominated perampanel in 65% of
simulations and had 91% and 92% probability
of being cost-effective at the willingness-to-pay
thresholds. Moreover, if brivaracetam and per-
ampanel were added on top of only one base
AED, brivaracetam had 76% dominance over
perampanel and was cost-effective with 90%
probability.
The results of our simulation analyses were
supported overwhelmingly by the clinical evi-
dence. Brivaracetam proved its efficacy and
rapid onset of therapeutic dose in the treatment
of focal onset seizures [25–28] while also pre-
serving good tolerance [22–28]. Even previous
treatment failure with levetiracetam does not
preclude the use of brivaracetam [30].
However, as always, modeled comparisons
have assumptions or simplifications, and our
study has the following five key limitations.
First, perampanel was included in the bri-
varacetam arm as a subsequent treatment
alternative, i.e., brivaracetam did not replace
perampanel but delayed its use in the base case
scenario. Thus, the drug costs were largely dri-
ven by subsequent treatment with perampanel
and not by brivaracetam itself. When peram-
panel was omitted from the brivaracetam arm,
the cost-effectiveness of brivaracetam improved
significantly.
Second, a maximum of three concurrent
AEDs were modeled, and all other subsequent
treatment alternatives were more affordable in
terms of drug costs than the brivaracetam or
perampanel, thus favoring perampanel in the
present analyses. In more recent clinical prac-
tice, use of three or more concurrent AEDs is
discouraged as much as possible, depending on
the patient’s disease severity. In the sensitivity
analysis scenario where brivaracetam and
perampanel were added to only one base AED,
brivaracetam dominated perampanel compared
with ICER €5345 per QALY gained in the base
case scenario where brivaracetam and peram-
panel were added to two base AEDs.
Third, the simulated AED costs were also
based on the lowest prices and most economic
package sizes; AED doses were based on pub-
lished Finnish data wherever available; poten-
tial AED titration costs were incurred as a one-
off cost at the start of treatment with the AED;
AEDs were not tapered down, and withdrawal to
monotherapy was not allowed. No interaction
was modeled between the treatment effects of
AEDs at adjunctive therapy, i.e., treatment
effect was no different between patients receiv-
ing one or two base AEDs at baseline. AED effi-
cacy was also unaffected by response or
discontinuation of previously received AEDs. In
addition, base AEDs remained unchanged dur-
ing the modeled time horizon. These simplifi-
cations favored perampanel in the present
comparison.
Fourth, early TEAEs that cause discontinua-
tion during the titration and response assess-
ment periods were simulated, and the effects of
early or late TEAEs not leading to discontinua-
tion were assumed to be negligible. When early
TEAEs do not cause treatment discontinuation,
the discontinuation in the long term was
modeled separately using similar time-varying
data for all AEDs based on the NICE (2011)
guidance model [48]. In the published studies,
treatment retention rates were 69.8% and
63.3% at 52 weeks after the initiation of active
treatment with brivaracetam and perampanel,
respectively [70]. In the current simulation
study TEAEs had no impact on HRQoL. This was
because TEAEs were assumed to be short-lived as
the AED causing TEAEs was withdrawn. These
simplifications favored perampanel in the
comparison.
Fifth, drug-resistant epilepsy has a significant
impact on the individuals’ everyday function-
ing, activities, and working capability. However,
this analysis used payer perspective based on
the official Finnish guidance [34, 35]. In real
life, the register-based traditional indirect costs
overwhelm the direct costs of epilepsy [15],
which were not considered in the base case
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analyses. The amount and proportion of indi-
rect costs can be even more profound than that
traditionally estimated, because the indirect
costs based on registers alone can significantly
underestimate the total societal cost or eco-
nomic burden. In a recent Finnish study that
also included a wider perspective, total indirect
costs of long-term diseases were four-fold those
of indirect costs observed directly based on
conventional national registers [51, 52]. Thus,
the applied base case perspective also favored
perampanel as was demonstrated by the mod-
eled traditional and wider societal perspective
sensitivity analyses. In both instances, bri-
varacetam dominated perampanel, and consid-
erable changes in the expected total 5-year costs
were observed (2.5–2.6-fold and 8.2–8.8-fold,
respectively). The applied perspective and its
potential implicit effects or biases should be
considered in the interpretation of the present
findings. More research is required in terms of
perspectives.
Finally, more treatment options for focal
onset seizures are needed. Brivaracetam has
been shown to be cost-effective in the Finnish
setting. In the real-world setting, brivaracetam
is relatively easy to use, titration is not needed,
the therapeutic dose is achieved quickly, and
tolerability is good. Thus, brivaracetam is
expected to be well suited to: encompassing
agile and digitalized social and health care ser-
vices [38, 39, 71, 72], risk-sharing [73] if needed
in some settings, and the requirements of
PICOSTEPS-based review [36]. In all of these,
the patient is at the center; furthermore, easy
applicability and follow-up of treatment are
valued. Overall, the analyses with traditional
register-based and considerably wider societal
perspective indicate that the direct health care
costs alone have limited effects and that society
should be more willing to invest in larger scale
studies of epilepsy-related indirect costs and
losses and on how to avoid them.
CONCLUSIONS
There is a significant unmet need for new, safe,
and effective epilepsy treatments. This simu-
lated cost-utility analysis, based on clinical trial
findings and payer perspective, indicated that
brivaracetam is likely to be both cost-effective
and net beneficial in the treatment of focal
onset seizures compared with perampanel. The
simulations also show that earlier treatment
with brivaracetam resulted in better cost-effec-
tiveness for brivaracetam. Brivaracetam may
also provide a cost-effective alternative to
treating focal onset seizures with perampanel in
other countries, but studies in such settings are
needed for confirmation.
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